1008-186 Encapsulation of pravastatin tablets produces greater low-density lipoprotein cholesterol lowering in patients with human immunodeficiency virus infection dyslipidemia taking protease inhibitors  by Ito, Matthew K et al.
446A ABSTRACTS - Vascular Disease, Hypertension, and Prevention JACC  March 3, 2004
Va
sc
ul
ar
 D
is
ea
se
, H
yp
er
te
ns
io
n,
 a
nd
 P
re
ve
nt
io
n
Conclusion: The net effect of ezetimibe/simvastatin is to inhibit cholesterol synthesis
and the absorption of phytosterols (in conjunction with cholesterol). Clinical relevance
and implications with respect to atherosclerosis development and progression warrant
further studies.
1008-184 The Effects of Pravastatin and Atorvastatin on Markers 
of Oxidant Stress In Vivo
Bonnie Ky, Megan L. Wolfe, Anne Burke, Philippe O. Szapary, Muredach P. Reilly, 
Jennifer B. Dykhouse, Leanne T. Bloedon, Garret A. FitzGerald, Daniel J. Rader, 
University of Pennsylvania School of Medicine, Philadelphia, PA
Treatment with inhibitors of 3-hydroxy-3methylglutaryl coenzyme reductase(statins)
decreases low density lipoprotein (LDL) cholesterol, but their effects on oxidative stress
are unclear.We performed a randomized, controlled clinical trial in which subjects
received pravastatin 40, atorvastatin 10, atorvastatin 80 or placebo therapy with the goal
of assessing the effects of statins on markers of oxidant stress. METHODS: 120 patients
(68 males and 52 females) between the ages of 21-80 with an LDL cholesterol between
130-220 mg/dl without known atherosclerotic disease, diabetes mellitus, chronic renal
insufficiency, or exposure to prior lipid lowering therapy were recruited. Patients were ran-
domized to one of the four arms and treated for 16 weeks. At baseline and 16 weeks,
plasma oxidized LDL was measured using a commercially available ELISA assay and uri-
nary isoprostanes were determined using GC/MS. RESULTS: After 16 weeks, reductions
in LDL cholesterol with statin therapy were as expected. With regards to changes in oxi-
dized LDL, pravastatin 40mg led to an 18.8% reduction, atorvastatin 10mg led to a 28%
reduction and atorvastatin 80mg led to a 32% reduction. In the placebo group, there was
a nonsignificant change in oxidized LDL over 16 weeks (3.65 %). However, there were no
significant changes in urinary isoprostane levels across all treatment arms. CONCLU-
SIONS: Pravastatin and atorvastatin led to statistically significant decreases in plasma
oxidized LDL concomitant with changes in LDL cholesterol, but did not lead to reductions
in urinary isoprostane excretion.
1008-185 Benefit of Statins in Secondary Prevention After Acute 
Myocardial Infarction: Evidence of a Class Effect
Zheng Zhou, Elham Rahme, Jack Tu, Karin Humphries, Mark Eisenberg, Michal 
Abrahamowicz, Peter Austin, Louise Pilote, Montreal General Hospital, Montreal, PQ, 
Canada, Institute for Clinical Evaluation Science, Toronto, ON, Canada
Background: Clinical trials have shown several statins to improve survival after acute
myocardial infarction (AMI). However whether all statins have a similar effect in reducing
recurrent AMI and death remains unclear. We conducted a population-based study to
assess whether a class effect exists among statins for secondary prevention. Methods:
A retrospective cohort study (1997~2002) was used to compare 5 statins based on the
hospital discharge and prescription claims databases from 3 provinces of Canada (Que-
bec, Ontario and British Columbia). The cohort consisted of patients > 65 years with a
first-recorded AMI since 1997. The effect of statin use on outcome was evaluated using a
Cox survival model adjusting for patient demographic and clinical characteristics as well
as specialty of treating physician, hospital type and the year of AMI. Switching, stopping
treatment and dosage change were also analysed. Result: A total of 18,637 statin users
were studied with a median follow-up of 2.5 years [atorvastatin (n=6420), pravastatin
(n=4480), simvastatin (n=5518), lovastatin (n=1736) and fluvastatin (n=483)]. Similar
baseline characteristics and statin usage patterns were found across different statin
groups and provinces. Compared to atorvastatin, the hazard ratios and 95% confidence
intervals for recurrent MI or death whichever occurred first revealed an equivalent effect
among statins: pravastatin 1.00 (0.90- 1.11), simvastatin 1.01 (0.91-1.12), lovastatin 1.09
(0.95-1.24) and fluvastatin 1.01(0.80-1.27). The conclusion remained unchanged when
studying all-cause mortality alone while treating recurrent MI as a time dependent covari-
ate. Censoring patients at switching or stopping treatment did not alter the results. Con-
clusion: Our results suggested that, despite the differences in their chemical structure
and metabolic properties, a beneficial class effect can be assumed for statins in the sec-
ondary prevention post AMI.
1008-186 Encapsulation of Pravastatin Tablets Produces Greater 
Low-Density Lipoprotein Cholesterol Lowering in 
Patients With Human Immunodeficiency Virus Infection 
Dyslipidemia Taking Protease Inhibitors
Matthew K. Ito, Victoria E. Aldridge, Jennifer J. Howard, Eric K. Gupta, Scott T. Johns, 
Joseph K. Wong, University of the Pacific, Stockton, CA, VA San Diego Healthcare 
System, San Diego, CA
Background: Dyslipidemia is well recognized in patients with Human Immunodeficiency
Virus (HIV) disease receiving antiretroviral therapy. Pravastatin is moderately effective at
reducing LDL cholesterol and has documented efficacy in reducing cardiovascular
events. Biotransformation of pravastatin occurs primarily by isomerization in the gut to a
relatively inactive (1/40 the reductase inhibitory activity) metabolite (SQ31,906). We have
shown that this biotransformation contributes to interindividual variability in the reduction
in LDL cholesterol. It is suggested that encapsulating or enteric coating pravastatin may
reduce this biotransformation and increase the efficacy of the drug.
Methods: We randomized 12 adult males with HIV to pravastatin 10 mg tablets either
encapsulated (placed within gel capsule with lactose) or non-encapsulated for 4 weeks
and were crossed-over following a 4 week washout.
Results: Lipid and pharmacokinetic parameters are shown in the table. Encapsulation of
pravastatin produced greater reductions in total (22% vs 12%, p=0.012) and LDL (25 %
vs 13%, p=0.021) cholesterol compared to non-encapsulation. The one hour post dose
ratio of plasma pravastatin to SQ31,906 were higher (2.2 vs 1.1, p=0.061) following
encapsulation compared to non-encapsulation. No differences in C-reactive protein (hs-
CRP) were noted.
Conclusion: Encapsulation of pravastatin significantly improves its LDL-lowering effi-
cacy by reducing biotransformation to SQ31,906.
1008-187 Effect of Pravastatin on Endothelial Function in Human 
Immunodeficiency Virus-Infected Persons on Protease 
Inhibitor-Containing Antiretroviral Combination Therapy
David Hurlimann, Jr., Remy Chenevard, Frank Ruschitzka, Sr., Jorg Muntwyler, Sr., 
Thomas Luscher, Sr., Georg Noll, Sr., Markus Flepp, Jr., Bruno Ledergerber, Sr., Rainer 
Weber, Sr., University Hospital Zurich, Zurich, Switzerland
Background: Antiretroviral combination therapy has altered cardiovascular risks and
manifestations in HIV-infected persons. Protease inhibitors in particular have been linked
to dyslipidemia, glucose intolerance, an increase in cardiovascular events and endothe-
lial dysfunction. Treatment of the pro-atherogenic lipid profile as well as improving endot-
helial function may be important for the long-term prognosis of these patients. The aim of
this study was to evaluate the effects of pravastatin on endothelial function and plasma
lipid profile.
Methods: 31 patients (mean age 45 ±9.3 years) with HIV-1 infection who were treated
with stable proteinase inhibitor-containing antiretroviral combination therapy for at least 4
months were randomly assigned to receive pravastatin 40mg daily or matching placebo
for 8 weeks in a double-blind cross-over fashion. Flow-mediated vasodilation (FMD) of
the brachial artery was assessed by high-resolution ultrasound at baseline and after
each treatment period, and plasma lipid levels were measured.
Results: Pravastatin significantly improved flow-mediated dilation compared to baseline
after 8 weeks treatment (3.2±1.6% vs. 2.3±1.0%, p=0.003). Further, improvement in
endothelial function was superior to placebo (3.2±1.6% vs. 2.5±1.2%, p=0.013). Total
cholesterol was lowered from 6.6±1.1 to 5.6±1.1mmol/l (-14.8%) p<0.0001) and LDL
from 3.7±0.9 to 3.1±0.9mmol/l (-16.3%) p=0.0003. Alterations in flow-mediated dilation
were inversely correlated to changes in LDL cholesterol (r=0.36, p=0.014). 
Conclusions: Our study demonstrates that pravastatin in HIV patients improves PI-con-
taining HAART associated endothelial dysfunction. The observed effects on the vascular
endothelium seem at least in part to be mediated by lowering LDL cholesterol. Thus,
pravastatin might hold the potential to improve prognosis in HIV infected patients with
protease inhibitor induced dyslipidemia.
1008-188 Trends in Use of Statins in Older Patients With Heart 
Failure
JoAnne M. Foody, Deron Galusha, Frederick A. Masoudi, Saif S. Rathore, Edward P. 
Havranek, Harlan M. Krumholz, Yale University School of Medicine, New Haven, CT
Background: Statin therapy improves outcomes in patients with ischemic cardiomyopathy
and may improve cardiac function and functional class in patients with idiopathic dilated
cardiomyopathy irrespective of serum cholesterol levels or atherosclerotic heart disease.
Little is known regarding trends in the use of statins in a population-based sample of
older patients with heart failure.
Methods and Results: In national cohorts of 39,477 and 39,405 older patients hospital-
ized between 1998-9 and 2000-1 respectively with heart failure, we assessed change in
rates of use of statins at discharge in patients surviving to discharge without contraindi-
cations to statins. Overall, 11.9% and 21.8% of patients were discharged in 1998-9 and
2000-1, respectively. While patients with prior history of PTCA or CABG were more likely
to receive these agents, as were those with elevated total cholesterol, women and the
Sterol Pbo (n=62) EZE 10 mg 
(n=55)
Simva (n=232) EZE 10 mg + 
Simva (n=229)
% 
change
Ratio % 
change
Ratio % 
change
Ratio % 
change
Ratio
Sitosterol -0.5 -4.1 -46.5* -37.8* -3.3 21.4* -52.1** -25.1†
Campesterol -2.0 -6.8 -50.5* -78.6* -1.6 39.8* -60.7** -68.3†
Lathosterol 4.7 2.7 35.5* 36.8* -53.5* -37.8 -47.6 -22.1†
Desmosterol 6.5 5.1 16.1 25.7* 48.0* -22.8 -45.6 -11.1†
Simva: pool of all doses of Simva. Comparisons: EZE & Simva vs Pbo; EZE+Simva vs 
Simva
% change: Mean % change. Ratio: Mean change (102 mmol/mol)
*P<0.001 vs Pbo; †P<0.001 vs Simva (pooled)
Encapsulated Non-encapsulated p-value
Total cholesterol (mean % change + sd)
LDL cholesterol (mean % change + sd)
HDL cholesterol (mean % change + sd)
triglycerides (mean % change + sd)
hs-CRP (median % change)
pravastatin/SQ31,906 (mean + sd)
-22 + 12
-25 + 9
-1 + 11
-8 + 36
-12
2.2 + 2
-12 + 9
-13 + 16
3 + 13
-19 + 25
17
1.2 + 0.7
0.012
0.021
0.23
0.21
0.21
0.061
